Neil Versel

The Swedish bioinformatics firm is targeting February 2025 for regulatory approval of its Qlucore Diagnostics software for transcriptomics-based ALL testing.

The specialty EHR vendor is building a two-way interface with Tempus as a model for incorporating genomic test ordering and results return into oncology workflows.

Initial results from a multinational rapid WGS newborn screening program are promising, though organizers hope to create a longitudinal study to support potential clinical uptake.

The genetic testing firm is using AI to improve genome interpretation and help customers raise low reimbursement rates for whole-exome testing.

The molecular diagnostics firm saw 38 percent growth in testing volume in Q2 but missed the Wall Street revenue consensus as it lost $116.1 million.

Six weeks after a management shakeup, the proteomics firm is looking for unspecified "inorganic" opportunities to become profitable.

Molecular diagnostic testing volume grew across all continuing operations in Q1 as GeneDx completed the shutdown of underperforming Sema4 assets.

With $13 million in new funding in hand, the small bioinformatics company aims to take on Big Pharma and will look to partner with major molecular labs.

In a new paper, computational biologists at Toronto's Hospital for Sick Children described their atlas of childhood cancer subtypes and a corresponding search tool.

The firm reiterated an earlier forecast of $205 million to $220 million in revenues for 2023, representing a slight decline over 2022.